JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gill, N.
Right arrow Articles by Ashkar, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gill, N.
Right arrow Articles by Ashkar, A. A.

 Previous Article  |  Next Article 

Journal of Virology, October 2006, p. 9943-9950, Vol. 80, No. 20
0022-538X/06/$08.00+0     doi:10.1128/JVI.01036-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Induction of Innate Immunity against Herpes Simplex Virus Type 2 Infection via Local Delivery of Toll-Like Receptor Ligands Correlates with Beta Interferon Production

Navkiran Gill, Philip M. Deacon, Brian Lichty, Karen L. Mossman, and Ali A. Ashkar*

Centre for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada

Received 19 May 2006/ Accepted 4 August 2006

Toll-like receptors (TLRs) constitute a family of innate receptors that recognize and respond to a wide spectrum of microorganisms, including fungi, bacteria, viruses, and protozoa. Previous studies have demonstrated that ligands for TLR3 and TLR9 induce potent innate antiviral responses against herpes simplex virus type 2 (HSV-2). However, the factor(s) involved in this innate protection is not well-defined. Here we report that production of beta interferon (IFN-ß) but not production of IFN-{alpha}, IFN-{gamma}, or tumor necrosis factor alpha (TNF-{alpha}) strongly correlates with innate protection against HSV-2. Local delivery of poly(I:C) and CpG oligodeoxynucleotides induced significant production of IFN-ß in the genital tract and provided complete protection against intravaginal (IVAG) HSV-2 challenge. There was no detectable IFN-ß in mice treated with ligands for TLR4 or TLR2, and these mice were not protected against subsequent IVAG HSV-2 challenge. There was no correlation between levels of TNF-{alpha} or IFN-{gamma} in the genital tract and protection against IVAG HSV-2 challenge following TLR ligand delivery. Both TNF-{alpha}–/– and IFN-{gamma}–/– mice were protected against IVAG HSV-2 challenge following local delivery of poly(I:C). To confirm that type I interferon, particularly IFN-ß, mediates innate protection, mice unresponsive to type I interferons (IFN-{alpha}/ßR–/– mice) and mice lacking IFN regulatory factor-3 (IRF-3–/– mice) were treated with poly(I:C) and then challenged with IVAG HSV-2. There was no protection against HSV-2 infection following poly(I:C) treatment of IFN-{alpha}/ßR–/– or IRF-3–/– mice. Local delivery of murine recombinant IFN-ß protected C57BL/6 and IRF-3–/– mice against IVAG HSV-2 challenge. Results from these in vivo studies clearly suggest a strong correlation between IFN-ß production and innate antiviral immunity against HSV-2.


* Corresponding author. Mailing address: Centre for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University Health Sciences Centre, Hamilton L8N 3Z5, Ontario, Canada. Phone: (905) 525-9140, ext. 22311. Fax: (905) 522-6750. E-mail: ashkara{at}mcmaster.ca.


Journal of Virology, October 2006, p. 9943-9950, Vol. 80, No. 20
0022-538X/06/$08.00+0     doi:10.1128/JVI.01036-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.